---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-039098"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:40:47.491098+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Virpax CMO Jeffrey Gudin resigns as officer, continues as director; receives $81,900 severance

## Summary
- Jeffrey Gudin resigned as Chief Medical Officer and EVP on May 2, 2024; no disagreement cited.
- Separation agreement provides $81,900 paid semi-monthly over six months plus COBRA reimbursement.
- Unvested options for 5,358 shares will continue to vest; total options for 20,616 shares.
- Gudin remains a Class III Director of the company.
- Agreement includes general release and non-disparagement clauses.

## SEC filing metadata
- accession: 0001213900-24-039098
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390024039098/0001213900-24-039098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390024039098/ea0205136-8k_virpax.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-039098
- JSON: https://secwatch.observer/filing/0001213900-24-039098.json
- Plain text: https://secwatch.observer/filing/0001213900-24-039098.txt

## Key facts
- Executive change
  Jeffrey Gudin resigned as Chief Medical Officer and Executive Vice President at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Medical Officer and Executive Vice President
  source text: On May 2, 2024, Virpax Pharmaceuticals, Inc. (the “Company”) entered into a Separation Agreement and Release, dated May 2, 2024 (the “Separation Agreement”), with Jeffrey Gudin, MD pursuant to which Dr. Gudin resigned from his positions of Chief Medical Officer and Executive Vice President of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390024039098/0001213900-24-039098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.